Outer membrane vesicle vaccines
Outer Membrane Vesicles (OMV) have received increased attention in recent years as a vaccine platform against bacterial pathogens. OMV from Neisseria meningitidis serogroup B have been extensively explored. Following the success of the MeNZB OMV vaccine in controlling an outbreak of N. meningitidis...
| Principais autores: | , |
|---|---|
| Formato: | Journal article |
| Idioma: | English |
| Publicado em: |
Elsevier
2020
|
| _version_ | 1826260003226386432 |
|---|---|
| author | Micoli, F MacLennan, CA |
| author_facet | Micoli, F MacLennan, CA |
| author_sort | Micoli, F |
| collection | OXFORD |
| description | Outer Membrane Vesicles (OMV) have received increased attention in recent years as a vaccine platform against bacterial pathogens. OMV from Neisseria meningitidis serogroup B have been extensively explored. Following the success of the MeNZB OMV vaccine in controlling an outbreak of N. meningitidis B in New Zealand, additional research and development resulted in the licensure of the OMV-containing four-component 4CMenB vaccine, Bexsero. This provided broader protection against multiple meningococcal B strains. Advances in the field of genetic engineering have permitted further improvements in the platform resulting in increased yields, reduced endotoxicity and decoration with homologous and heterologous antigens to enhance immuno genicity and provide broader protection. The OMV vaccine platform has been extended to many other pathogens. In this review, we discuss progress in the development of the OMV vaccine delivery platform, highlighting successful applications, together with potential challenges and gaps. |
| first_indexed | 2024-03-06T18:58:44Z |
| format | Journal article |
| id | oxford-uuid:12cad63c-02da-42de-adb4-f7f6fcedd51d |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T18:58:44Z |
| publishDate | 2020 |
| publisher | Elsevier |
| record_format | dspace |
| spelling | oxford-uuid:12cad63c-02da-42de-adb4-f7f6fcedd51d2022-03-26T10:10:03ZOuter membrane vesicle vaccinesJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:12cad63c-02da-42de-adb4-f7f6fcedd51dEnglishSymplectic ElementsElsevier2020Micoli, FMacLennan, CAOuter Membrane Vesicles (OMV) have received increased attention in recent years as a vaccine platform against bacterial pathogens. OMV from Neisseria meningitidis serogroup B have been extensively explored. Following the success of the MeNZB OMV vaccine in controlling an outbreak of N. meningitidis B in New Zealand, additional research and development resulted in the licensure of the OMV-containing four-component 4CMenB vaccine, Bexsero. This provided broader protection against multiple meningococcal B strains. Advances in the field of genetic engineering have permitted further improvements in the platform resulting in increased yields, reduced endotoxicity and decoration with homologous and heterologous antigens to enhance immuno genicity and provide broader protection. The OMV vaccine platform has been extended to many other pathogens. In this review, we discuss progress in the development of the OMV vaccine delivery platform, highlighting successful applications, together with potential challenges and gaps. |
| spellingShingle | Micoli, F MacLennan, CA Outer membrane vesicle vaccines |
| title | Outer membrane vesicle vaccines |
| title_full | Outer membrane vesicle vaccines |
| title_fullStr | Outer membrane vesicle vaccines |
| title_full_unstemmed | Outer membrane vesicle vaccines |
| title_short | Outer membrane vesicle vaccines |
| title_sort | outer membrane vesicle vaccines |
| work_keys_str_mv | AT micolif outermembranevesiclevaccines AT maclennanca outermembranevesiclevaccines |